7 research outputs found
CRITICAL ISSUES OF PAPILLOMA VIRUS INFECTION PREVENTION
The article details the issue of malignancy caused by human papilloma virus (HPV), as well as characteristics of this virus. Its genetic stability allows for efficient prevention of this pathology through vaccination. 2 vaccines, which are approved by the FDA end EMEA for use and are registered in Russia, have been created and are successfully used for this purpose. The authors believe that the best results may be achieved by combining screening examination programmes with universal reasonable administration of scheduled voluntary vaccination of Russiaβs population.Key words: human papilloma virus, HPV infection, cervical cancer, malignancies, prevention, vaccination
CERVICAL CANCER IS NOT A CHILDREN'S ILLNESS, ISN'T IT?
The authors highlight the foreign authors review about the spread and peculiarities of the HPV infection and HPV'associated uterine cervix impairment in teenage girls. The interaction between HPV infection and uterine cervix impairment were described. There are also the most important prevention approaches in this issue. Key words: human papilloma virus, uterine cervix impairment, cervical cancer, screening, vaccination, teenage girls
CERVICAL CANCER IS NOT A CHILDREN'S ILLNESS, ISN'T IT?
The authors highlight the foreign authors review about the spread and peculiarities of the HPV infection and HPV'associated uterine cervix impairment in teenage girls. The interaction between HPV infection and uterine cervix impairment were described. There are also the most important prevention approaches in this issue. Key words: human papilloma virus, uterine cervix impairment, cervical cancer, screening, vaccination, teenage girls
CRITICAL ISSUES OF PAPILLOMA VIRUS INFECTION PREVENTION
The article details the issue of malignancy caused by human papilloma virus (HPV), as well as characteristics of this virus. Its genetic stability allows for efficient prevention of this pathology through vaccination. 2 vaccines, which are approved by the FDA end EMEA for use and are registered in Russia, have been created and are successfully used for this purpose. The authors believe that the best results may be achieved by combining screening examination programmes with universal reasonable administration of scheduled voluntary vaccination of Russiaβs population.Key words: human papilloma virus, HPV infection, cervical cancer, malignancies, prevention, vaccination
Π ΠΠ Π¨ΠΠΠΠ ΠΠΠ’ΠΠ - ΠΠ ΠΠΠ’Π‘ΠΠΠ― ΠΠΠΠΠΠΠ¬
The authors highlight the foreign authors review about the spread and peculiarities of the HPV infection and HPV'associated uterine cervix impairment in teenage girls. The interaction between HPV infection and uterine cervix impairment were described. There are also the most important prevention approaches in this issue. Key words: human papilloma virus, uterine cervix impairment, cervical cancer, screening, vaccination, teenage girls.Π ΡΡΠ°ΡΡΠ΅ ΠΈΠ·Π»ΠΎΠΆΠ΅Π½Ρ ΡΠΈΡΡΠ΅ΠΌΠ°ΡΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ Π·Π°ΡΡΠ±Π΅ΠΆΠ½ΡΡ
Π°Π²ΡΠΎΡΠΎΠ², ΠΊΠ°ΡΠ°ΡΡΠΈΠ΅ΡΡ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΠΈ ΠΈ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ Π΅ΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΠΠ§-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΈ ΠΠΠ§-Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠΉ ΡΠ΅ΠΉΠΊΠΈ ΠΌΠ°ΡΠΊΠΈ Ρ Π΄Π΅Π²ΠΎΡΠ΅ΠΊ-ΠΏΠΎΠ΄ΡΠΎΡΡΠΊΠΎΠ². ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π° Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·Ρ ΠΠΠ§-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΈ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠΉ ΡΠ΅ΠΉΠΊΠΈ ΠΌΠ°ΡΠΊΠΈ Ρ ΡΠΈΡΠΊΠΎΠ²ΡΠΌ ΠΏΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ΠΌ ΠΏΠΎΠ΄ΡΠΎΡΡΠΊΠΎΠ²; ΠΏΡΠΈΠ²Π΅Π΄Π΅Π½Ρ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π²Π°ΠΆΠ½ΡΠ΅ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΈΡ
ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ.ΠΠ»ΡΡΠ΅Π²ΡΠ΅ ΡΠ»ΠΎΠ²Π°: Π²ΠΈΡΡΡ ΠΏΠ°ΠΏΠΈΠ»Π»ΠΎΠΌΡ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°, Π΄Π΅Π²ΠΎΡΠΊΠΈ-ΠΏΠΎΠ΄ΡΠΎΡΡΠΊΠΈ, ΡΠΈΡΠΊΠΎΠ²ΠΎΠ΅ ΠΏΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅, ΠΈΠ½ΡΡΠ°ΡΠΏΠΈΡΠ΅Π»ΠΈΠ°Π»ΡΠ½ΡΠ΅ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ Π½ΠΈΠ·ΠΊΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ (LSIL), ΠΈΠ½ΡΡΠ°ΡΠΏΠΈΡΠ΅Π»ΠΈΠ°Π»ΡΠ½ΡΠ΅ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ Π²ΡΡΠΎΠΊΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ (HSIL), ΡΠ°ΠΊ ΡΠ΅ΠΉΠΊΠΈ ΠΌΠ°ΡΠΊΠΈ, ΡΠΊΡΠΈΠ½ΠΈΠ½Π³, Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΡ. (ΠΠ΅Π΄ΠΈΠ°ΡΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΠΈΡ 2009;6(3):29-35)
ΠΠΠ’Π£ΠΠΠ¬ΠΠ«Π ΠΠΠΠ ΠΠ‘Π« ΠΠ ΠΠ€ΠΠΠΠΠ’ΠΠΠ ΠΠΠΠΠΠΠΠΠΠΠΠ Π£Π‘ΠΠΠ ΠΠΠ€ΠΠΠ¦ΠΠ
The article details the issue of malignancy caused by human papilloma virus (HPV), as well as characteristics of this virus. Its genetic stability allows for efficient prevention of this pathology through vaccination. 2 vaccines, which are approved by the FDA end EMEA for use and are registered in Russia, have been created and are successfully used for this purpose. The authors believe that the best results may be achieved by combining screening examination programmes with universal reasonable administration of scheduled voluntary vaccination of Russiaβs population.Key words: human papilloma virus, HPV infection, cervical cancer, malignancies, prevention, vaccination.Π ΡΡΠ°ΡΡΠ΅ ΠΏΠΎΠ΄ΡΠΎΠ±Π½ΠΎ ΠΎΡΠ²Π΅ΡΠ°ΡΡΡΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ, Π²ΡΠ·Π²Π°Π½Π½ΡΡ
Π²ΠΈΡΡΡΠΎΠΌ ΠΏΠ°ΠΏΠΈΠ»Π»ΠΎΠΌΡ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° (ΠΠΠ§), Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° ΡΠ°ΠΌΠΎΠ³ΠΎ Π²ΠΈΡΡΡΠ°. ΠΠ³ΠΎ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΡΠ°Π±ΠΈΠ»ΡΠ½ΠΎΡΡΡ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°Π΅Ρ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ Π΄Π°Π½Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΏΡΡΠ΅ΠΌ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ. ΠΠ»Ρ ΡΡΠΎΠΉ ΡΠ΅Π»ΠΈ ΡΠΆΠ΅ ΡΠΎΠ·Π΄Π°Π½Ρ ΠΈ ΡΡΠΏΠ΅ΡΠ½ΠΎ ΠΏΡΠΈΠΌΠ΅Π½ΡΡΡΡΡ 2 Π²Π°ΠΊΡΠΈΠ½Ρ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΎΠ΄ΠΎΠ±ΡΠ΅Π½Ρ ΠΊ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ FDA, ΠΠΠΠ ΠΈ Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½Ρ Π² Π ΠΎΡΡΠΈΠΈ. ΠΠ²ΡΠΎΡΡ ΡΡΠΈΡΠ°ΡΡ, ΡΡΠΎ Π½Π°ΠΈΠ»ΡΡΡΠΈΡ
ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΌΠΎΠΆΠ½ΠΎ Π΄ΠΎΡΡΠΈΡΡ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ΠΌ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³ΠΎΠ²ΡΡ
ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Ρ ΠΏΠΎΠ²ΡΠ΅ΠΌΠ΅ΡΡΠ½ΠΎΠΉ ΡΠ°Π·ΡΠΌΠ½ΠΎΠΉ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠ΅ΠΉ ΠΏΠ»Π°Π½ΠΎΠ²ΠΎΠΉ Π΄ΠΎΠ±ΡΠΎΠ²ΠΎΠ»ΡΠ½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ Π ΠΎΡΡΠΈΠΈ.ΠΠ»ΡΡΠ΅Π²ΡΠ΅ ΡΠ»ΠΎΠ²Π°: Π²ΠΈΡΡΡ ΠΏΠ°ΠΏΠΈΠ»Π»ΠΎΠΌΡ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°, ΠΠΠ§-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡ, ΡΠ°ΠΊ ΡΠ΅ΠΉΠΊΠΈ ΠΌΠ°ΡΠΊΠΈ, Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ, ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ°, Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΡ.(ΠΠ΅Π΄ΠΈΠ°ΡΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΠΈΡ 2011;8(1):17-21
Inositols: pharmacology and findings of clinical trials. Current evidence and prospects
Yu.E. Dobrokhotova1, O.A. Gromova2, A.S. Dukhanin1, Z.Kh. Kumykova3, E.V. Sheremetyeva4, G.I. Tabeeva3
1Pirogov Russian National Research Medical University, Moscow, Russian Federation
2Federal Research Center "Informatics and Management" of the Russian Academy of Sciences, Moscow, Russian Federation
3V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russian Federation
4National Medical Research Center of Endocrinology, Moscow, Russian Federation
Alterations in reproductive functions are associated with metabolic disorders, eating habits and lifestyle. In this context, a growing body of research is currently focused on the use of various vitamins and vitamin-like substances, such as inositol, in female patients with alterations in reproductive functions and metabolic disorders. Co-administration of inositol with pathogenetic therapy can be recommended to women of reproductive age with metabolic syndrome, as an additional option for preserving fertility and activating ovarian functions in young female patients with diminished ovarian reserve. Myoinositol and D-chiroinositol are inositol stereoisomers demonstrating the highest metabolic activity. The beneficial ratio of Myoinositol (MI) to D-chiroinositol (DCI) ensures the healthy state of organs and tissues, while a misbalance or depletion of inositol levels can cause various diseases. Combination of MI and DCI in a 5:1 ratio with manganese and folic acid is an original non-hormonal formula designed to improve functional state of the female reproductive system as well as carbohydrate and lipid metabolism. In addition, this combination should be considered as a promising alternative for the management of metabolic disorders in perimenopausal women.
Keywords: reproductive function, metabolism, inositol, myoinositol, D-chiroinositol, polycystic ovary syndrome, ovarian reserve, menopause, metabolic syndrome, manganese, folic acid.
For citation: Dobrokhotova Yu.E., Gromova O.A., Dukhanin A.S. et al. Inositols: pharmacology and findings of clinical trials. Current evidence and prospects. Russian Journal of Woman and Child Health. 2022;5(4):309β319 (in Russ.). DOI: 10.32364/2618-8430-2022-5-4-309-319.
<br